AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Steinbach, W. J.
Right arrow Articles by Perfect, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Steinbach, W. J.
Right arrow Articles by Perfect, J. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2004, p. 1664-1669, Vol. 48, No. 5
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.5.1664-1669.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

In Vitro Interactions between Antifungals and Immunosuppressants against Aspergillus fumigatus

William J. Steinbach,1* Wiley A. Schell,2 Jill R. Blankenship,3 Chiatogu Onyewu,4 Joseph Heitman,3,4,5 and John R. Perfect2

Division of Pediatric Infectious Diseases, Department of Pediatrics,1 Division of Infectious Diseases and International Health, Department of Medicine,2 Department of Molecular Genetics and Microbiology,3 Department of Pharmacology and Cancer Biology,4 The Howard Hughes Medical Institute, Duke University Medical Center, Durham, North Carolina 277105

Received 8 October 2003/ Returned for modification 24 December 2003/ Accepted 19 January 2004

The optimal treatment for invasive aspergillosis remains elusive, despite the increased efficacy of newer agents. The immunosuppressants cyclosporine (CY), tacrolimus (FK506), and sirolimus (formerly called rapamycin) exhibit in vitro and in vivo activity against Candida albicans, Cryptococcus neoformans, and Saccharomyces cerevisiae, including fungicidal synergy with azole antifungals. We report here that both FK506 and CY exhibit a clear in vitro positive interaction with caspofungin against Aspergillus fumigatus by disk diffusion, microdilution checkerboard, and gross and microscopic morphological analyses. Microscopic morphological analyses indicate that the calcineurin inhibitors delay filamentation, and in combination with caspofungin there is a positive interaction. Our findings suggest a potential role for combination therapy with calcineurin pathway inhibitors and existing antifungal agents to augment activity against A. fumigatus.


* Corresponding author. Mailing address: Division of Pediatric Infectious Diseases, Box 3499, Duke University Medical Center, Durham, NC 27710. Phone: (919) 684-6335. Fax: (919) 416-9268. E-mail: stein022{at}mc.duke.edu.


Antimicrobial Agents and Chemotherapy, May 2004, p. 1664-1669, Vol. 48, No. 5
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.5.1664-1669.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2004 by the American Society for Microbiology. All rights reserved.